Brought to you by 
Medeva obtains rights to Chiesi's Pulvinal dry inhaler
13 Jul 1999
Executive Summary
Medeva obtained exclusive marketing rights in the US and Canada to Chiesi Farmaceutici's albuterol (salbutamol) and beclomethasone multi-dose Pulvinal dry powder inhalers, for which it will pay Chiesi royalties on sales.
Deal Industry
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Medeva obtains rights to Chiesi's Pulvinal dry inhaler
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice